Perseus Proteomics Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	-716	-902	-1,102	-785	-597
Depreciation & Amortization	-	2	3	5	2
Loss (Gain) From Sale of Assets	37	72	153	95	117
Other Operating Activities	50	-1	-1	-	-
Change in Accounts Receivable	4	-8	-3	-	-1
Change in Inventory	-1	-	-1	-	-1
Change in Accounts Payable	-34	8	1	22	10
Change in Other Net Operating Assets	7	110	117	99	-6
Operating Cash Flow	-653	-719	-833	-564	-476
Capital Expenditures	-9	-75	-143	-164	-33
Sale (Purchase) of Intangibles	-	-	-15	-6	-
Other Investing Activities	-1	-	8	-42	-
Investing Cash Flow	-10	-75	-150	-212	-33
Issuance of Common Stock	503	927	63	-	2,652
Other Financing Activities	-6	-4	-	-	-5
Financing Cash Flow	497	923	63	-	2,647
Foreign Exchange Rate Adjustments	13	-2	16	7	8
Miscellaneous Cash Flow Adjustments	1	-1	1	-	-1
Net Cash Flow	-152	126	-903	-769	2,145
Free Cash Flow	-662	-794	-976	-728	-509
Free Cash Flow Margin	-490.37%	-661.67%	-976.00%	-774.47%	-716.90%
Free Cash Flow Per Share	-44.41	-55.65	-82.80	-61.91	-46.29
Cash Income Tax Paid	2	1	1	1	1
Levered Free Cash Flow	-518.63	-592.25	-736.38	-631.63	-249.63
Unlevered Free Cash Flow	-518.63	-592.25	-736.38	-631.63	-249.63
Change in Working Capital	-24	110	114	121	2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.